Skip to content

ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control

The Use of fluticasone Propionate/Salmeterol Inhaler With Integrated Dose Counter and Smartphone Self Management to Improve Airway Inflammation and Asthma Control

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02556073
Enrollment
112
Registered
2015-09-22
Start date
2014-08-31
Completion date
2016-12-31
Last updated
2015-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma control, adherence, asthma self management plan, airway inflammation

Brief summary

Poor adherence to asthma controller medication may link to poor asthma outcome. A metered dose device with built-in dose counter helps physicians to monitor drug compliance in asthma patients. Mobile-phone based self management opens a window for better asthma control. The present study aims to investigate the relationship between the adherence to controller medication of combined inhaled corticosteroid/long acting beta2-agonists, assessing by integrated dose counter, and the level of airway inflammation and asthma control. Moreover, the investigators also use a new asthma self-management Apps to enhance drug compliance. With the application of the new, easily available tools, the investigator expect to increase adherence rates, and hence, to reduce airway inflammation and improve the level of asthma control.

Detailed description

The study will be conducted as a prospective, observational, open labeled, randomized trial in a single center (Taipei Veterans General Hospital). After screening, the enrolled patients will be randomized to either routine care or Smartphone self management group. In the routine care group, the patient will be treated as routine practice as a real-world setting. No additional intervention will be done. In the Smartphone self management group, an asthma self management Apps (My asthma App, GlaxoSmithKline, Chinese version, or Line), which provides multiple function, including health information (real-time weather condition, air pollution index) at the point-of-living, personalized health assessments (asthma control test, peak flow rate) and interactive action plans (green, yellow, and red light), and regular reminding for controller administration, will be downloaded to the participant's Smartphone. The participant will be educated to operate the Apps to improve asthma control. Participants in both groups will use identical controller (Sal/flu 2 inhalations twice daily plus as-needed rescue ventolin) and will be scheduled to follow up for 24 weeks.

Interventions

OTHERSmartphone action

Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.

DRUGusual care

fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed

Sponsors

Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Symptomatic asthmatics free of controller medication for at least 3 months 2. Aged from 20 to 70 years 3. Life-long smoking index \< 10 pack-years

Exclusion criteria

1. COPD, clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease. 2. A chest X-ray indicating diagnosis other than asthma that might interfere with the study. 3. Major disease abnormalities are uncontrolled on therapy. 4. Alcohol or medication abuse. 5. Patients had lower respiratory tract infections or received systemic steroid in the 4 weeks prior to the commencement of study. 6. Unable or unwilling to comply with all protocol 7. Unable to use Smartphone

Design outcomes

Primary

MeasureTime frameDescription
Changes of airway inflammation profileChanges of airway inflammation profile from baseline at 24 weeksmeasurement including exhaled NO, cell counts and mediator in induced sputum before (baseline, wk0) and after treatment (wk 24)

Secondary

MeasureTime frameDescription
changes of scores of asthma control questionnaireChanges of scores of asthma control questionnaire from baseline at 24 weeksscores of questionnaire of asthma control test (ACT)
Changes of lung function parametersChanges of lung function parameters (FEV1, FVC) from baseline at 24 weeks
Numbers of rescue medication useTotal numbers of rescue medication use during 24-week period

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026